J&J expects double-digit 2023 profit growth after Kenvue spinoff
(Reuters) -Johnson & Johnson on Wednesday forecast double-digit profit growth for…
N2:PHMR
US FTC suspends challenge to block Amgen’s $27.8 billion deal…
(Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its challenge of…
US govt awards $1.4 billion for development of new COVID therapies,…
(Reuters) - The U.S. government said on Tuesday it had awarded $1.4 billion for the…
AbbVie trims forecast for Humira sales drop on favorable coverage
By Leroy Leo and Patrick Wingrove (Reuters) -AbbVie on Thursday trimmed its 2023 view for…
J&J upbeat on 2023 as devices rebound post-COVID, shares jump
By Bhanvi Satija and Patrick Wingrove (Reuters) -Johnson & Johnson on Thursday…
Acumen’s Alzheimer’s drug passes initial safety test
By Julie Steenhuysen CHICAGO (Reuters) - An experimental Alzheimer's disease drug…
US FDA grants standard approval of Eisai/Biogen Alzheimer’s drug
By Deena Beasley and Julie Steenhuysen LOS ANGELES (Reuters) -Eisai and Biogen's…
Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
By Ludwig Burger FRANKFURT (Reuters) - Novartis breast cancer drug Kisqali cut the risk of…
Exclusive-US to build $300 million database to fuel Alzheimer’s…
By Julie Steenhuysen CHICAGO (Reuters) - The U.S. National Institute on Aging (NIA) is…